High Growth Tech Stocks In The United States To Watch

The market has been flat over the last week but is up 31% over the past year, with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and scalability while aligning with these positive market trends.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
Super Micro Computer	20.63%	25.42%	★★★★★★
Sarepta Therapeutics	23.80%	44.01%	★★★★★★
TG Therapeutics	34.66%	56.48%	★★★★★★
Invivyd	47.87%	67.72%	★★★★★★
Amicus Therapeutics	20.26%	62.89%	★★★★★★
Alkami Technology	21.90%	98.60%	★★★★★★
Alnylam Pharmaceuticals	22.41%	70.53%	★★★★★★
Travere Therapeutics	31.20%	72.26%	★★★★★★
Seagen	22.57%	71.80%	★★★★★★
ImmunoGen	26.00%	45.85%	★★★★★★

Click here to see the full list of 241 stocks from our US High Growth Tech and AI Stocks screener.

Let's uncover some gems from our specialized screener.

Mirum Pharmaceuticals (NasdaqGM:MIRM)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments for rare and orphan diseases, with a market cap of $1.94 billion.

Operations: Mirum Pharmaceuticals focuses on developing and commercializing therapies for rare and orphan diseases, generating $264.38 million in revenue from its pharmaceuticals segment.

Mirum Pharmaceuticals, despite its current unprofitable status, is on a trajectory to reverse this trend within the next three years with expected profitability and an impressive forecasted revenue growth of 24.9% annually. This growth rate surpasses the US market average of 8.8%, positioning Mirum favorably in the biotech sector. The company's commitment to innovation is evident from its significant R&D expenditure, which supports promising projects like volixibat—a potential treatment for cholestatic pruritus in primary biliary cholangitis patients that recently received FDA Breakthrough Therapy Designation. This designation underscores the drug's potential to outperform existing therapies significantly, further evidenced by positive interim results from ongoing studies indicating substantial patient improvement without severe adverse effects.

• Click to explore a detailed breakdown of our findings in Mirum Pharmaceuticals' health report.

• Gain insights into Mirum Pharmaceuticals' past trends and performance with our Past report.

Arcutis Biotherapeutics (NasdaqGS:ARQT)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Arcutis Biotherapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing treatments for dermatological diseases with a market cap of $1.02 billion.

Operations: Arcutis Biotherapeutics focuses on the development and commercialization of pharmaceutical treatments for dermatological diseases, generating revenue primarily from its pharmaceuticals segment, which reported $132.06 million.

Arcutis Biotherapeutics has recently showcased promising results with its ZORYVE cream 0.15%, significantly impacting patient outcomes in atopic dermatitis (AD) treatment. At the ACAAI Annual Scientific Meeting, they revealed that 64.2% of patients achieved a clinically meaningful improvement in the SCORAD Total Score by Week 1, reflecting rapid and effective symptom management. This performance is underpinned by a robust R&D commitment, evidenced by their recent announcement on October 18 about receiving Health Canada's approval for ZORYVE foam for seborrheic dermatitis, expanding their dermatological portfolio further. With revenue projected to grow at an impressive rate of 34.6% annually and earnings expected to surge by 69.1% per year, Arcutis is positioning itself as a notable entity in dermatological solutions despite current unprofitability.

• Get an in-depth perspective on Arcutis Biotherapeutics' performance by reading our health report here.

• Explore historical data to track Arcutis Biotherapeutics' performance over time in our Past section.

Ascendis Pharma (NasdaqGS:ASND)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Ascendis Pharma A/S is a biopharmaceutical company dedicated to developing therapies for unmet medical needs, with a market capitalization of $7.52 billion.

Operations: Ascendis Pharma focuses on developing therapies for unmet medical needs, generating revenue primarily from its biotechnology segment, which contributed €317.63 million.

Ascendis Pharma's strategic partnership with Novo Nordisk, leveraging its TransCon technology for metabolic and cardiovascular diseases, marks a pivotal expansion in high-growth sectors. This collaboration could potentially bring in up to $285 million from the lead program alone, with additional financial benefits tied to other product candidates. Moreover, Ascendis' recent FDA submission for TransCon hGH indicates a proactive approach in addressing adult growth hormone deficiency, complementing their pediatric applications and underscoring their commitment to innovative therapeutic solutions across various age groups. Their focused R&D efforts are set to enhance their market presence significantly, reflecting a promising trajectory despite current unprofitability.

• Unlock comprehensive insights into our analysis of Ascendis Pharma stock in this health report.

• Examine Ascendis Pharma's past performance report to understand how it has performed in the past.

Where To Now?

• Explore the 241 names from our US High Growth Tech and AI Stocks screener here.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com